152 related articles for article (PubMed ID: 30543914)
1. Oral administration of leeches (Shuizhi): A review of the mechanisms of action on antiplatelet aggregation.
Qiu J; Lingna W; Jinghong H; Yongqing Z
J Ethnopharmacol; 2019 Mar; 232():103-109. PubMed ID: 30543914
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of platelet activation and potential therapeutic effects of natural drugs.
Zhou Y; Zhang D; Tan P; Xian B; Jiang H; Wu Q; Huang X; Zhang P; Xiao X; Pei J
Phytomedicine; 2023 Jan; 108():154463. PubMed ID: 36347177
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregation.
Tomizawa A; Ohno K; Jakubowski JA; Mizuno M; Sugidachi A
Thromb Haemost; 2013 Oct; 110(4):769-76. PubMed ID: 23903326
[TBL] [Abstract][Full Text] [Related]
4. Traditional uses, phytochemistry, pharmacology and toxicology of Codonopsis: A review.
Gao SM; Liu JS; Wang M; Cao TT; Qi YD; Zhang BG; Sun XB; Liu HT; Xiao PG
J Ethnopharmacol; 2018 Jun; 219():50-70. PubMed ID: 29501674
[TBL] [Abstract][Full Text] [Related]
5. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
6. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
8. The Operculina macrocarpa (l.) urb. (jalapa) tincture modulates human blood platelet aggregation.
Pierdoná TM; Lima NR; Rodrigues RC; Teixeira JP; Gonçalves RP; Fontenele JB; Vasconcelos SM; de Barros Viana GS; Leal LK
J Ethnopharmacol; 2014; 151(1):151-7. PubMed ID: 24201020
[TBL] [Abstract][Full Text] [Related]
9. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
10. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
11. Development of a DHA-Losartan hybrid as a potent inhibitor of multiple pathway-induced platelet aggregation.
Tsiailanis AD; Vrettos EI; Choleva M; Kiriakidi S; Ganai AM; Patha TK; Karpoormath R; Mavromoustakos T; Fragopoulou E; Tzakos AG
J Biomol Struct Dyn; 2022; 40(24):13889-13900. PubMed ID: 34791990
[TBL] [Abstract][Full Text] [Related]
12. Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Caiazzo G; De Rosa S; Torella D; Spaccarotella C; Mongiardo A; Giampà S; Micieli M; Palella E; Gulletta E; Indolfi C
Circ Cardiovasc Interv; 2014 Feb; 7(1):104-12. PubMed ID: 24449597
[TBL] [Abstract][Full Text] [Related]
13. [Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice].
Buriachkovskaia LI; Uchitel' IA; Sumarokov AV; Popov EG
Ter Arkh; 2009; 81(5):41-7. PubMed ID: 19537585
[TBL] [Abstract][Full Text] [Related]
14. W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.
Ge P; Du L; Han C; Li H; Feng Y; Han J; Wang Z; Xiong L; Yuan M; Liu Y
J Cardiovasc Pharmacol; 2017 Feb; 69(2):110-117. PubMed ID: 27930430
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium.
Lau AJ; Toh DF; Chua TK; Pang YK; Woo SO; Koh HL
J Ethnopharmacol; 2009 Sep; 125(3):380-6. PubMed ID: 19665534
[TBL] [Abstract][Full Text] [Related]
16. [Comparative evaluation of antiplatelet efectiveness drugs of original and reproduced enteric forms of acetylsalicylic acid (clinical study ICAR))].
Martsevich SIu; Tolpygina SN; Lukina IuV; Voronina VP; Kiseleva NV; Boĭchenko ES; Dubinskaia RÉ; Khoseva EN
Kardiologiia; 2012; 52(1):74-82. PubMed ID: 22304357
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
18. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
19. Review of aspirin and clopidogrel resistance in peripheral arterial disease.
Guirgis M; Thompson P; Jansen S
J Vasc Surg; 2017 Nov; 66(5):1576-1586. PubMed ID: 28893489
[TBL] [Abstract][Full Text] [Related]
20. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice.
Kashiwagi H; Yuhki K; Kojima F; Kumei S; Takahata O; Sakai Y; Narumiya S; Ushikubi F
J Pharmacol Exp Ther; 2015 May; 353(2):269-78. PubMed ID: 25740898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
